Ventyx Biosciences (VTYX) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Ventyx Biosciences in August 2026.
Ventyx Biosciences, Inc. (VTYX) is a small‑cap biotechnology company listed in the US market with a market capitalisation of about $268.12 million. As an R&D‑focused issuer, Ventyx’s value is driven primarily by its scientific pipeline, clinical‑trial progress, regulatory milestones and partnerships rather than steady operating profits. Biotech stocks of this size often experience high volatility: positive trial news or regulatory approvals can lift the share price quickly, while setbacks, funding needs or disappointing data can lead to sharp declines. Income investors should not expect dividends; returns typically come from capital appreciation. Before considering any exposure, investors should review the company’s latest filings, understand the clinical stage of its programmes, assess cash runway and funding plans, and be comfortable with possible dilution and binary event risk. This summary is for general educational purposes only and is not personalised investment advice — values can rise and fall and past performance is not a reliable indicator of future results.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Ventyx Biosciences' stock as its target price indicates limited growth potential.
Financial Health
Ventyx Biosciences is showing strong financial performance with solid cash flow and book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Small‑cap dynamics
Market moves can be large and rapid for a ~$268m company, offering potential upside but also heightened volatility and liquidity risk.
Pipeline & trials
Clinical progress and regulatory news typically drive value. Check trial phases and read peer comparisons, though outcomes can be binary.
Funding considerations
R&D costs may require future capital raises, which can dilute shareholders; assess cash runway and management funding plans.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.